I-cell disease

Jump to navigation Jump to search
I-cell disease
ICD-10 E77.0
ICD-9 272.7
OMIM 252500
DiseasesDB 29175
MeSH D009081

WikiDoc Resources for I-cell disease


Most recent articles on I-cell disease

Most cited articles on I-cell disease

Review articles on I-cell disease

Articles on I-cell disease in N Eng J Med, Lancet, BMJ


Powerpoint slides on I-cell disease

Images of I-cell disease

Photos of I-cell disease

Podcasts & MP3s on I-cell disease

Videos on I-cell disease

Evidence Based Medicine

Cochrane Collaboration on I-cell disease

Bandolier on I-cell disease

TRIP on I-cell disease

Clinical Trials

Ongoing Trials on I-cell disease at Clinical Trials.gov

Trial results on I-cell disease

Clinical Trials on I-cell disease at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on I-cell disease

NICE Guidance on I-cell disease


FDA on I-cell disease

CDC on I-cell disease


Books on I-cell disease


I-cell disease in the news

Be alerted to news on I-cell disease

News trends on I-cell disease


Blogs on I-cell disease


Definitions of I-cell disease

Patient Resources / Community

Patient resources on I-cell disease

Discussion groups on I-cell disease

Patient Handouts on I-cell disease

Directions to Hospitals Treating I-cell disease

Risk calculators and risk factors for I-cell disease

Healthcare Provider Resources

Symptoms of I-cell disease

Causes & Risk Factors for I-cell disease

Diagnostic studies for I-cell disease

Treatment of I-cell disease

Continuing Medical Education (CME)

CME Programs on I-cell disease


I-cell disease en Espanol

I-cell disease en Francais


I-cell disease in the Marketplace

Patents on I-cell disease

Experimental / Informatics

List of terms related to I-cell disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and Keywords: mucolipidosis II; ML II


Inclusion-cell (I-cell) disease is so named because waste products, thought to include carbohydrates, lipids, and proteins, accumulate into masses known as inclusion bodies. When tissues are examined under a microscope, the detection of inclusion bodies often provides a diagnosis of the disease.


I-cell disease is caused by a defect in mannose phosphorylation of lysosomal enzymes. Without mannose-6-phosphate to target them to the lysosomes, the enzymes are transported from the endoplasmic reticulum to the extracellular space. It can be associate with GNPTA.[1]


ML II is a particularly severe form of ML that resembles one of the mucopolysaccharidoses called Hurler syndrome. Some physical signs, such as abnormal skeletal development, coarse facial features, and restricted joint movement, may be present at birth. Children with ML II usually have enlargement of certain organs, such as the liver or spleen, and sometimes even the heart valves. Affected children often fail to grow and develop in the first months of life. Delays in the development of their motor skills are usually more pronounced than delays in their cognitive (mental processing) skills. Children with ML II eventually develop a clouding on the cornea of their eyes and, because of their lack of growth, develop short-trunk dwarfism (underdeveloped trunk). These young patients are often plagued by recurrent respiratory tract infections, including pneumonia, otis media (middle ear infections), and bronchitis. Children with ML II generally die before their seventh year of life, often as a result of congestive heart failure or recurrent respiratory tract infections.

See also


  1. Tiede S, Storch S, Lübke T; et al. (2005). "Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase". Nat. Med. 11 (10): 1109–12. doi:10.1038/nm1305. PMID 16200072.

Template:Endocrine, nutritional and metabolic pathology

ca:Malaltia de les cèl·lules I

Template:WikiDoc Sources